Weight-loss weariness and Trump threats wipe $250bn off Novo Nordisk and Eli Lilly
Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise
Related reading
US to slash prices of obesity drugs offered on Trump website
White House’s landmark deal with Novo Nordisk and Eli Lilly will cut costs from at least $1,000 to about $350
Novo Nordisk shares slide as Trump vows to cut Ozempic price
US administration is in negotiations over cost of Danish group’s best-selling obesity drug
Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk
Two groups fight for edge in one of the most lucrative drug classes in pharmaceutical industry history
White House launches TrumpRx as drug companies warn of sales hit
Platform offers discounts for weight-loss and fertility medicines sold by Novo Nordisk, Eli Lilly and others
Novo Nordisk shares plunge after profit warning over US weight-loss copycats
Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy
Eli Lilly shot helped patients lose 29% of body weight
Trial results are a boost to US pharmaceutical company’s booming obesity business